The goal of this clinical trial is to improve the treatment of hepatic steatosis associated with obesity with pharmacological and nutritionnal approaches. The main question it aims to answer is:
Does an individualized nutritionnal approach with a dietician combined with medication targeting obesity is the most efficient way to treat hepatic steatosis associated with obesity?
Participants will either participate in one of three groups:
* Nutrition: Participant will only have a regular follow-up with a registered dietician; * Nutrition + Semaglutide: Participants will start a new medication targeting obesity and will have a regular follow-up with a registered dietician; * Semaglutide: Participants will start a new medication targeting obesity.
Body mass index between 30 and 50 kg/m2;
Stade 2 or 3 (S2 or S3) hepatic steatosis with or without liver fibrosis.
Type 1 diabetes diagnosis;
Alcohol consumption exceeding recommendations [>140 g/week (women) and >210 g/week (men)];
Known chronic hepatic disease non-steatotic at the entry of the study (Wilson's disease, hemochromatosis, alpha-1-antitrypsin deficiency, viral hepatitis, auto-immune hepatitis, etc.);
Pharmacological treatment targeting obesity active or ended in the last 3 months;
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Lead sponsor